Acumen Pharmaceuticals (ABOS)
NASDAQ:ABOS
ABOS Stock Chart & Stats
$2.55
-$0.08(-4.37%)
At close: 4:00 PM EST
$2.55
-$0.08(-4.37%)
Day’s Range― - ―
52-Week Range$0.86 - $3.60
Previous CloseN/A
Volume101.31K
Average Volume (3M)415.59K
Market Cap
$154.46M
Enterprise Value$109.24M
Total Cash (Recent Filing)$116.86M
Total Debt (Recent Filing)$8.77M
Price to Earnings (P/E)―
Beta2.17
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding60,573,425
10 Day Avg. Volume506,634
30 Day Avg. Volume415,590
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.81
Price to Sales (P/S)0.00
P/FCF Ratio-1.11
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue-1.21K
Enterprise Value/Gross Profit-2.43K
Enterprise Value/Ebitda-0.93
Forecast
1Y Price Target
$6.67Price Target Upside161.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.65
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Funding And Regulatory SignalsA recent private placement provides funding to advance the shuttle program, and regulatory acceptance of subcutaneous induction filings for similar antibodies indicates growing support for more convenient dosing options.
Oligomer-targeted Antibody DesignAntibody candidates demonstrate strong preference for toxic amyloid-beta oligomers over plaque and monomers, which could neutralize the most harmful species while reducing plaque-related side effects.
Preclinical Brain-penetration DataNon-human primate studies show substantially higher brain penetration for enhanced brain delivery candidates, supporting a potential efficacy advantage for therapies that reach their target in the brain.
Bears Say
Brain Swelling Risk Unchanged By Subcutaneous DosingThe subcutaneous formulation does not appear to reduce the primary brain swelling risk compared with intravenous dosing, leaving the overall risk–benefit profile constrained.
Early-stage Program Commercial ImpactNext-generation antibody programs are at an early stage and are unlikely to contribute to the company's first marketed product, which limits near-term commercial impact.
Surrogate Endpoint Reliance In Subcutaneous FilingsA subcutaneous filing that depends on showing similar plaque removal rather than direct cognitive benefit risks delaying clear evidence of clinical improvement if high initial drug exposure is required.
Acumen Pharmaceuticals News
ABOS FAQ
What was Acumen Pharmaceuticals’s price range in the past 12 months?
Acumen Pharmaceuticals lowest stock price was $0.85 and its highest was $3.60 in the past 12 months.
What is Acumen Pharmaceuticals’s market cap?
Acumen Pharmaceuticals’s market cap is $154.46M.
When is Acumen Pharmaceuticals’s upcoming earnings report date?
Acumen Pharmaceuticals’s upcoming earnings report date is May 19, 2026 which is in 53 days.
How were Acumen Pharmaceuticals’s earnings last quarter?
Acumen Pharmaceuticals released its earnings results on Mar 26, 2026. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.453 by $0.053.
Is Acumen Pharmaceuticals overvalued?
According to Wall Street analysts Acumen Pharmaceuticals’s price is currently Undervalued.
Does Acumen Pharmaceuticals pay dividends?
Acumen Pharmaceuticals does not currently pay dividends.
What is Acumen Pharmaceuticals’s EPS estimate?
Acumen Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acumen Pharmaceuticals have?
Acumen Pharmaceuticals has 60,573,425 shares outstanding.
What happened to Acumen Pharmaceuticals’s price movement after its last earnings report?
Acumen Pharmaceuticals reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.453. Following the earnings report the stock price went down -3.042%.
Which hedge fund is a major shareholder of Acumen Pharmaceuticals?
Currently, no hedge funds are holding shares in ABOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acumen Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.67 (161.57% Upside)
$6.67 (161.57% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.87%
12-Months-Change
Fundamentals
Return on Equity
-97.41%
Trailing 12-Months
Asset Growth
-46.73%
Trailing 12-Months
Company Description
Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
ABOS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials, strategic partnerships, and financial management, with a focus on advancing Alzheimer's treatments. However, the operational loss was a noted concern.View all ABOS earnings summariesABOS Stock 12 Month Forecast
Average Price Target
$6.67
▲(161.57% Upside)
Technical Analysis
Ownership Overview
28.62% Insiders
7.71% Mutual Funds
39.92% Other Institutional Investors
21.14% Public Companies and
Individual Investors